GLP-1 boosts insulin secretion from pancreatic beta cells in a glucose-dependent manner (meaning it only works when blood glucose is elevated, reducing hypoglycemia risk), suppresses glucagon secretion from pancreatic alpha cells (reducing glucose production by the liver), slows gastric emptying (prolonging satiety and reducing postprandial glucose spikes), and starts GLP-1 receptors in the brain (very the hypothalamus) to reduce appetite and food intake
Limitations and strengths This study is based on comprehensive longitudinal data from multiple nationwide registries in Denmark, where information can be linked across registries due to the unique personal identification number
doi:10.1007/s13300-020-00894-y 45
The majority of T2D management is in primary care [4], where clinicians (medical, nursing and pharmacist staff) are uniquely placed to use their generalist expertise to partner with individuals with T2D to develop a treatment plan to address their needs and help achieve treatment goals
Some combinations interact, and high-dose protocols carry more risk